NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
6.62
+0.27 (4.25%)
Sep 21, 2026, 4:00 PM EDT - Market closed
NeuroSense Therapeutics Employees
NeuroSense Therapeutics had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$654,412
Market Cap
12.24M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - |
| Dec 31, 2024 | 17 | -1 | -5.56% |
| Dec 31, 2023 | 18 | 4 | 28.57% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| Daré Bioscience | 24 |
| BioLineRx | 24 |
| Theriva Biologics | 16 |
| BioVie | 13 |
| MetaVia | 8 |
| AEON Biopharma | 8 |
| Phio Pharmaceuticals | 6 |
NRSN News
- 10 days ago - Neurosense Therapeutics Ltd trading halted, news pending - TheFly
- 11 days ago - NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference - PRNewsWire
- 18 days ago - NeuroSense initiated with a Buy at H.C. Wainwright - TheFly
- 21 days ago - NeuroSense announces redesigned development plan for PrimeC - TheFly
- 21 days ago - NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS - PRNewsWire
- 5 weeks ago - NeuroSense Issues CEO Letter to Shareholders - PRNewsWire
- 6 weeks ago - NeuroSense sees December 2026 as filing date for NDS for PrimeC - TheFly
- 6 weeks ago - NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada - PRNewsWire